Dementia pathophysiology

Jump to navigation Jump to search

Dementia Microchapters

Patient Information

Overview

Classification

Causes

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: ,Sabeeh Islam, MBBS[2]

Overview

Chronic, progressive neurodegenerative disorder characterized by a global, nonreversible impairment in cerebral functioning. Deteriorating course over up to 8-10 years.

  • Brain lesions are marked by neurofibrillary tangles, senile plaques, neuronal loss, and brain atrophy, with defects in acetylcholine synthesis at the cellular level.
  • The ultimate neurotoxin in dementia is debated, but experimental evidence highlights small aggregates of amyloid beta peptides called oligomers, as opposed to larger aggregates called fibril[1]
  • Pathogenesis of dementia also involves a second protein, tau. The accumulation of this altered protein is toxic to neurons in experimental models.[2]
  • There are three alleles of APOE, called epsilon 2 (e2), e3, and e4, and their encoded isoforms also vary in several activities. One mechanism by which inheritance of the APOE e4 may increase dementia risk is by impairing amyloid beta clearance from cerebrum[3]


Pathophysiology

While the pathogenesis of AD remains unclear, It is thought that dementia is the result of

  • Overproduction and/or decreased clearance of amyloid beta peptides
  • Accumulation of tau proteins
  • Accumulation of neurofibrillary tangles
  • Production of oxygen radicals and nitric oxide, and inflammatory processes
  • Decreased levels of cholinergic neurotransmission.
  • Over-excitation of the glutamate neurotransmitter system via N-methyl-D-aspartate receptors

These changes are usually present in the hippocampus, amygdala, cortex, and nucleus basalis

Genes


Genes involved in the pathogenesis of dementia include

  • Amyloid precursor protein (APP)
  • Presenilin 1 (PSEN1)[4]
  • Presenilin 2 (PSEN2)
  • Apolipoprotein E (APOE)
  • C9ORF72
  • MAPT
  • GRN[5]

Dementia Microchapters

Patient Information

Overview

Classification

Causes

Differential Diagnosis

References

  1. Gremer L, Schölzel D, Schenk C, Reinartz E, Labahn J, Ravelli R, Tusche M, Lopez-Iglesias C, Hoyer W, Heise H, Willbold D, Schröder GF (October 2017). "Fibril structure of amyloid-β(1-42) by cryo-electron microscopy". Science. 358 (6359): 116–119. doi:10.1126/science.aao2825. PMID 28882996. Vancouver style error: initials (help)
  2. Guo JL, Lee VM (April 2011). "Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles". J Biol Chem. 286 (17): 15317–31. doi:10.1074/jbc.M110.209296. PMC 3083182. PMID 21372138.
  3. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (June 2011). "Human apoE isoforms differentially regulate brain amyloid-β peptide clearance". Sci Transl Med. 3 (89): 89ra57. doi:10.1126/scitranslmed.3002156. PMC 3192364. PMID 21715678.
  4. Whooley MA, Avins AL, Miranda J, Browner WS (July 1997). "Case-finding instruments for depression. Two questions are as good as many". J Gen Intern Med. 12 (7): 439–45. doi:10.1046/j.1525-1497.1997.00076.x. PMC 1497134. PMID 9229283.
  5. Arroll B, Khin N, Kerse N (November 2003). "Screening for depression in primary care with two verbally asked questions: cross sectional study". BMJ. 327 (7424): 1144–6. doi:10.1136/bmj.327.7424.1144. PMC 261815. PMID 14615341.

Template:WH Template:WS